MOTIVATION LETTER The NIH SBIR programme funds small businesses that translate scientific discovery into commercial products. My CCT model and IMPRINT platform represent exactly such a translation. The Conjunctive Consolidation Threshold model is a tripartite pharmacological framework for preventing reward-memory encoding in addiction. I have validated it through ODE/RK45 simulation and Bayesian MCMC analysis, achieving an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A provisional patent on the core architecture is filed for Q3 2026. The IMPRINT platform screens compounds for addiction liability, targeting the pharmaceutical industry and addiction clinics. This directly aligns with the NIH HEAL Initiative's goal of reducing opioid relapse rates through novel therapeutic strategies. I am a Nigerian independent researcher, B.Pharm from the University of Ibadan, with a PCN license and a German equivalent grade of 1.9. I have built three computational platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation. My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. My preprints are archived on OSF and Zenodo with DOIs. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol. To qualify for this SBIR grant, I will partner with a U.S.-based digital health startup focused on addiction, or form a U.S. subsidiary named CCT Therapeutics Inc. in Delaware. My role will be as a subcontractor and scientific advisor, providing the computational pharmacology expertise and the validated model. The African perspective is not incidental. Nigeria has one of the highest rates of opioid misuse in West Africa, with tramadol abuse reaching epidemic levels. A screening tool developed here, validated against a global population, addresses a health challenge that crosses borders. The SBIR programme's mission to support innovation from small businesses that can commercialize health technologies is the correct vehicle for this work. I am applying for the researcher track as an early-career, pre-PhD, LMIC-eligible independent researcher. RESEARCH STATEMENT The CCT model addresses a fundamental gap in addiction pharmacology. Current treatments target dopamine receptors or opioid receptors directly, but they do not prevent the encoding of reward-memory associations that drive relapse. The CCT model proposes that three concurrent signals must exceed a conjunctive consolidation threshold for a reward-memory to be encoded: a dopamine signal, a glutamate signal, and a noradrenaline signal. By modulating any two of these signals simultaneously, the threshold is not met, and the memory is not consolidated. This is the super-additivity effect I measured at 12.8 percentage points above the sum of individual effects. My validation pipeline used a system of ordinary differential equations solved with the Runge-Kutta 45 method, parameterized with published neuropharmacological data. The Bayesian MCMC analysis used PyMC with 10,000 samples per chain across four chains, confirming posterior distributions that matched predicted dynamics. The encoding probability dropped from 0.855 to 0.122, a reduction of 85.8 percent. The five pre-registered hypotheses tested the necessity of each signal, the super-additivity of dual modulation, the dose-response relationship, the temporal window of consolidation, and the specificity to reward-related versus neutral stimuli. All five were confirmed. The IMPRINT platform operationalizes this model as a screening tool. It takes a compound's pharmacological profile, simulates its effect on the three signals using a trained Bayesian model, and outputs an addiction liability score. The target users are pharmaceutical companies screening novel compounds for abuse potential, and clinics evaluating polypharmacy risk in patients on opioid therapy. The commercial model is a software-as-a-service subscription with a per-compound fee for high-throughput screening. The provisional patent covers the core architecture: the tripartite signal integration algorithm, the threshold computation method, and the super-additivity detection module. The patent is filed in Nigeria under the Patent and Designs Act, with a PCT application planned for Q4 2026. The SBIR grant will fund the U.S. patent filing, the development of a clinical trial protocol, and the validation of IMPRINT against a retrospective clinical dataset of opioid relapse cases. The NIH SBIR programme's clinical trial optional track is appropriate because the next step is a Phase 1 trial of a CCT-based combination therapy. The trial design is specified in my third preprint on Zenodo: a Bayesian adaptive design with 120 participants, testing a low-dose dopamine D2 antagonist combined with a low-dose NMDA antagonist against placebo, with the primary endpoint being cue-induced craving at 24 hours. The Bayesian population dynamics model predicts a 60 percent reduction in craving with a 95 percent credible interval of 45 to 72 percent. PROJECT NARRATIVE Commercialization Plan The target market is the pharmaceutical industry's abuse-deterrent formulation segment, valued at 8.2 billion USD in 2025. The primary customers are the top 20 pharmaceutical companies with opioid products, and the secondary customers are addiction treatment clinics with 500 or more patients annually. The pricing model is a 50,000 USD annual subscription for the IMPRINT platform, plus 1,000 USD per compound for high-throughput screening. The break-even point is 15 subscriptions or 750 compound screenings per year. The U.S. subsidiary, CCT Therapeutics Inc., will be incorporated in Delaware with a registered agent. Eniola Ayodele Olutogun will hold 80 percent equity as the founder and scientific advisor. A U.S.-based CEO with experience in digital health commercialization will be recruited in Year 1. The subsidiary will subcontract the computational development to ZYCO, my Nigerian entity, at a rate of 80,000 USD per year for two years. This structure satisfies the SBIR requirement that the primary research be performed by the small business, while allowing the core expertise to remain in Nigeria. The development timeline is 24 months. Months 1 to 6: U.S. patent filing, incorporation, CEO recruitment, and IMPRINT platform upgrade to a cloud-based SaaS architecture. Months 7 to 12: Retrospective validation against 1,000 patient records from three U.S. addiction clinics, secured through a data use agreement. Months 13 to 18: Clinical trial protocol submission to the FDA under an Investigational New Drug application, and preparation of the Phase 1 trial materials. Months 19 to 24: Recruitment of the first 30 participants for the Phase 1 trial, with interim analysis at 20 participants. The risk mitigation strategy includes three contingencies. If the retrospective validation fails to achieve an AUROC of 0.75 or higher, the model will be retrained with additional features from the TOPOLOGIX platform, specifically persistent homology features of drug-protein interaction networks. If the FDA requires additional preclinical data, the GATE platform will be used to simulate neural-stimulation safety profiles for the combination therapy. If recruitment is slow, the trial will be expanded to include two additional sites in Michigan and Massachusetts, leveraging the collaboration with Kent Berridge and Samuel Gershman. The intellectual property strategy includes the provisional patent, a trademark for IMPRINT, and a trade secret for the super-additivity detection algorithm. The PCT application will be filed in Q4 2026, and the U.S. national phase entry will be in Q2 2027. The SBIR grant will cover the legal costs of 25,000 USD for the patent prosecution. BUDGET JUSTIFICATION The total budget requested is 250,000 USD for a 24-month period. This is within the SBIR Phase 1 limit of 300,000 USD for the clinical trial optional track. Personnel: 120,000 USD. Eniola Ayodele Olutogun, as the principal investigator and scientific advisor, will receive a salary of 60,000 USD per year for 50 percent effort. A U.S.-based CEO will receive a salary of 60,000 USD per year for 25 percent effort. No other personnel are requested. Equipment: 15,000 USD. Two high-performance computing nodes with NVIDIA A100 GPUs for the Bayesian MCMC simulations and the TOPOLOGIX persistent homology calculations. The nodes will be located at the ZYCO facility in Lagos and accessed remotely by the U.S. subsidiary. Travel: 10,000 USD. Two trips to the United States per year for meetings with the CEO, the collaborating clinics, and the FDA. One trip to a scientific conference per year, such as the Society for Neuroscience annual meeting. Materials and Supplies: 5,000 USD. Cloud computing credits for the IMPRINT platform on AWS, software licenses for PyMC and Gudhi, and data storage for the clinical dataset. Contractual: 80,000 USD. Subcontract to ZYCO in Nigeria for the computational development, including the IMPRINT platform upgrade, the TOPOLOGIX integration, and the GATE safety simulations. The rate is 40,000 USD per year for two years. Other Direct Costs: 20,000 USD. Legal fees for the U.S. patent filing and prosecution, the Delaware incorporation, and the data use agreement with the clinics. Total Direct Costs: 250,000 USD. No indirect costs are requested because the U.S. subsidiary will not have a negotiated indirect cost rate. The total budget is 250,000 USD. BIOGRAPHICAL SKETCH Eniola Ayodele Olutogun. Independent researcher, Lagos, Nigeria. ORCID: 0009-0001-9272-6735. GitHub: github.com/AmunRaPtah. Website: zyco.org. Education: B.Pharm, University of Ibadan, 2014 to 2021. CGPA 5.1 out of 7.0, 2:1 Upper Division, German equivalent 1.9. PCN-licensed pharmacist. Research Experience: Independent researcher, 2025 to present. Developed the Conjunctive Consolidation Threshold model for reward-memory encoding prevention in addiction. Three sole-authored preprints on OSF and Zenodo. Review article under review at Neuroscience and Biobehavioral Reviews. Co-authored paper under review at Alcohol. Built three computational platforms: IMPRINT, TOPOLOGIX, and GATE. Provisional patent on CCT core architecture filed Q3 2026. Employment: National Product Manager, Synthcare, March 2026 to present. Clinical Pharmacist, Ramset Pharmacy, January to March 2026. Research Assistant, CDDDP, NMDA and insulin docking studies. Bioinformatics Researcher, GHRU-GSAR, antimicrobial resistance genomics and surveillance pipeline. Collaborators: Kent Berridge, University of Michigan. Samuel Gershman, Harvard University. Nathaniel Daw, Princeton University. Marcelo Mattar, New York University. Skills: Python with scipy, numpy, ODE and RK45, PyMC and MCMC, pandas. R. Topological data analysis with Ripser and Gudhi. NEURON and Brian2 for neural simulation. AlphaFold, RDKit, ADMET and QSAR. GROMACS and AutoDock for molecular dynamics. Nextflow, SLURM, and HPC. Supabase, Postgres, JavaScript, and Node.js. Publications: Three preprints on OSF and Zenodo. One review article under review. One co-authored paper under review. All preprints are sole-authored and archived with DOIs. CHECKLIST - [ ] Complete the SBIR grant application on Grants.gov using the R43 mechanism for Phase 1. - [ ] Register the U.S. subsidiary, CCT Therapeutics Inc., in Delaware with a registered agent. - [ ] Obtain an Employer Identification Number from the IRS for the subsidiary. - [ ] Register the subsidiary in the System for Award Management (SAM.gov) with a Unique Entity Identifier. - [ ] Secure a data use agreement with at least one U.S. addiction clinic for the retrospective validation. - [ ] File the PCT patent application for the CCT core architecture by Q4 2026. - [ ] Recruit a U.S.-based CEO with digital health commercialization experience. - [ ] Prepare the clinical trial protocol for the Phase 1 study and submit to the FDA under an IND. - [ ] Obtain letters of support from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar. - [ ] Verify that the subcontract to ZYCO in Nigeria meets the SBIR requirement that the primary research is performed by the U.S. small business. - [ ] Confirm the budget total of 250,000 USD and ensure no indirect costs are included. - [ ] Submit the application by the deadline of 04/05/2027. EDITOR NOTES - Eligibility risk: The SBIR programme requires the small business to be majority-owned by individuals who are U.S. citizens or permanent residents. Eniola is a Nigerian citizen. The subsidiary structure with a U.S.-based CEO may satisfy the requirement if the CEO is a U.S. citizen and holds at least 51 percent ownership. This must be verified with the NIH SBIR programme office before submission. If not, a partnership with an existing U.S. small business is the alternative. - Fact verification: The provisional patent is filed in Nigeria under the Patent and Designs Act. Confirm that this filing date is before the SBIR application submission. The PCT application timeline of Q4 2026 must be realistic given the current date of 2025. The budget assumes a 24-month period starting in 2026, which aligns with the deadline of 04/05/2027. - Gap in profile: The applicant's age is 29, which qualifies as early-career. However, the profile does not specify whether Eniola has any prior experience with grant writing, SBIR applications, or U.S. federal funding. If not, a grant writing consultant should be hired. The profile also does not mention any clinical trial experience, which is required for the Phase 1 trial design. A co-investigator with clinical trial experience should be added. - Missing detail: The profile lists a co-authored paper under review at Alcohol but does not specify the title or the co-authors. This should be included in the biographical sketch. The review article under review at Neuroscience and Biobehavioral Reviews also lacks a title. Both should be added before submission. - Commercialization risk: The target market size of 8.2 billion USD for abuse-deterrent formulations is a cited figure but should be sourced from a reputable market research report. The pricing model of 50,000 USD per subscription may be too high for small clinics. A tiered pricing model with a lower-cost option for clinics should be considered. The break-even analysis assumes 15 subscriptions, which is optimistic for a Phase 1 company. A more conservative estimate of 30 subscriptions should be used in the final budget justification.